{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:13:08Z","timestamp":1756167188611,"version":"3.44.0"},"reference-count":11,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Delays in cancer treatment can result in tumor growth, increased clonal heterogeneity, upstaging, increased symptoms, organ damage, increased psychological distress, and worse clinical outcomes. Evidence supported guidelines for treatment timeliness exist in many cancers, but not for multiple myeloma (MM) though there is reason to believe delays in treatment would be detrimental.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Aims<\/jats:title>\n<jats:p>This scoping review aims to explore what is known about the impacts of the time from diagnosis to treatment among patients with MM.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Our review will be guided by the Joanna Briggs Institute scoping review methodology. Our search strategy was developed to identify sources published in or after the year 2000 related to time to treatment for adults with newly diagnosed multiple myeloma in PubMed, CINAHL, Scopus and Embase. Sources will be screened by two independent reviewers after exclusion\/inclusion criteria are pilot tested and refined. A data extraction form was developed and will be refined by the study team for use during the scoping review.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Discussion<\/jats:title>\n<jats:p>This review will summarize the landscape of research related to time to treatment among newly diagnosed adults with multiple myeloma. Raising awareness of the available evidence on this topic, within the MM clinical and research community, will guide future research to address identified knowledge gaps.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec005\">\n<jats:title>Registration<\/jats:title>\n<jats:p>This protocol was registered with Open Science Framework (OSF) on the 25<jats:sup>th<\/jats:sup> of March, 2025 and can be found at <jats:bold>osf.io\/sydqw<\/jats:bold>.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0330907","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T17:22:22Z","timestamp":1756142542000},"page":"e0330907","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Protocol for a scoping review of time to treatment in adults with newly diagnosed multiple myeloma"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1270-3825","authenticated-orcid":true,"given":"Matthew R.","family":"LeBlanc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison O.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5961-4893","authenticated-orcid":true,"given":"Osborn Owusu","family":"Ansah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3527-9975","authenticated-orcid":true,"given":"Jamie","family":"Conklin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"issue":"3","key":"pone.0330907.ref001","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213209","article-title":"Time to initial cancer treatment in the United States and association with survival over time: An observational study","volume":"14","author":"AA Khorana","year":"2019","journal-title":"PLoS One"},{"issue":"12","key":"pone.0330907.ref002","article-title":"Assessment of time-to-treatment initiation and survival in a cohort of patients with common cancers","volume":"3","author":"EB Cone","year":"2020","journal-title":"JAMA Netw Open"},{"key":"pone.0330907.ref003","article-title":"Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review","author":"RD Neal","year":"2015","journal-title":"Br J Cancer"},{"issue":"1","key":"pone.0330907.ref004","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"RA Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"pone.0330907.ref005","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1080\/10428190902741471","article-title":"Diagnostic delay and complications for older adults with multiple myeloma","volume":"50","author":"CR Friese","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"pone.0330907.ref006","first-page":"5239","article-title":"A cross-sectional observational study of health-related quality of life in adults with multiple myeloma","volume":"30","author":"MR LeBlanc","year":"2022","journal-title":"Support Care Cancer"},{"issue":"10","key":"pone.0330907.ref007","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/qjmed\/hcm077","article-title":"Multiple myeloma: causes and consequences of delay in diagnosis","volume":"100","author":"CC Kariyawasan","year":"2007","journal-title":"QJM"},{"issue":"4","key":"pone.0330907.ref008","doi-asserted-by":"crossref","first-page":"953","DOI":"10.11124\/JBIES-21-00242","article-title":"Best practice guidance and reporting items for the development of scoping review protocols","volume":"20","author":"MDJ Peters","year":"2022","journal-title":"JBI Evid Synth"},{"key":"pone.0330907.ref009","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"L Shamseer","year":"2015","journal-title":"BMJ"},{"key":"pone.0330907.ref010","unstructured":"U.S. Food and Drug Administration. Hematology\/Oncology (Cancer) Approvals & Safety Notifications: U.S. Food and Drug Administration. 2023. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/oncology-cancer-hematologic-malignancies-approval-notifications"},{"issue":"7","key":"pone.0330907.ref011","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"AC Tricco","year":"2018","journal-title":"Ann Intern Med"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0330907","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T17:22:25Z","timestamp":1756142545000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0330907"}},"subtitle":[],"editor":[{"given":"Carmelo","family":"Caldarella","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":11,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0330907","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]}}}